Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

Investigating the Association Between Corticosteroid Use and Improvement in Doxorubicin Liposome-Induced Cutaneous Toxicity: Exploring the Feasibility and Mechanisms of Corticosteroids in Mitigating Liposomal Doxorubicin-Related Dermatologic Adverse Effects.

Trial Details

NCT ID
NCT07362914
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Dexamethasone (12mg d1)
  • Dexamethasone (2mg QD, d1-5,)
  • Doxorubicin hydrochloride liposome injection
  • Cyclophosphamide
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients aged 18-70 years (inclusive), regardless of gender.
  • Diagnosis \& Treatment Plan: Histopathologically confirmed early-stage or advanced breast cancer patients eligible for AC regimen (liposomal doxoru…
  • ECOG Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
  • Anticipated survival ≥3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →